The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ALLOGENE THERAPEUTICS, INC. | COM | 019770106 | 75,073 | 2,889,651 | SH | SOLE | 2,889,651 | 0 | 0 | ||
HOMOLOGY MEDICINES, INC. | COM | 438083107 | 15,956 | 770,845 | SH | SOLE | 770,845 | 0 | 0 | ||
SUTRO BIOPHARMA, INC. | COM | 869367102 | 10,951 | 995,579 | SH | SOLE | 995,579 | 0 | 0 | ||
OYSTER POINT PHARMA, INC. | COM | 69242L106 | 23,547 | 963,468 | SH | SOLE | 963,468 | 0 | 0 |